ClinicaliQ Trial Snapshot
- Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06940154.
- This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation.
- Sponsor: Connect Biopharm LLC.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Eligibility Snapshot
- : * Physician-diagnosed COPD with duration of ≥12 months. * Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids. * Participants in a stable condition must have a documented historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb. * Current or former smoker with a history of smoking of ≥10 pack-years. * Current acute COPD exacerbation requiring an urgent healthcare visit for treatment. * Peripheral blood eosinophil count of ≥300 cells/μL as part of the assessment of the index acute COPD exacerbation. * Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.